✨ Free AI Report
IDEAYA Biosciences, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research IDEAYA Biosciences, Inc.
Company Research

IDEAYA Biosciences, Inc.: Business Overview, Financials & Competitive Analysis

IDEAYA is a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies for cancer, integrating expertise in small-molecule drug discovery, structural...

Analyst-debate audio for IDEAYA Biosciences, Inc.

AskCyborg analysts argue the bull and bear cases for IDEAYA Biosciences, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
7/ 10Strong

Cyborg Score thesis

Well-capitalized precision oncology biotech with differentiated ADC/synthetic lethality pipeline targeting high unmet needs and...

Read the full analyst-debate transcript →
Industry Precision Medicine Oncology / Biotech
3 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest IDEAYA Biosciences, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

IDEAYA Biosciences, Inc. Overview

Pro stress-test →

IDEAYA is a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies for cancer, integrating expertise in small-molecule drug discovery, structural biology and bioinformatics with translational biomarker capabilities. The company has built a deep pipeline of product candidates focused on synthetic lethality and antibody-drug conjugates (ADCs) for molecularly defined solid tumor indications.

Strategic Profile

Pro stress-test →

2025 marked a year of execution with broad pipeline advancement and commercial readiness activities for darovasertib, supported by a deep pipeline and cash runway into 2030 addressing multiple indications with high unmet need including uveal melanoma, small cell lung cancer, neuroendocrine cancer, breast cancer, and MTAP-deleted cancers. In 2026, the company plans to advance four registrational trials, including IDE849 (DLL3 TOP1 ADC) in neuroendocrine cancer and darovasertib in uveal melanoma, a poorest prognosis oncology indication where the majority of patients have no available FDA approved therapies.

Competitive Landscape

Pro stress-test →

IDEAYA focuses on synthetic lethality and ADC-based approaches for molecularly defined solid tumors, competing within the broader precision oncology and ADC therapeutic spaces. The company differentiates through its dual-target bispecific ADC platform and focus on difficult-to-treat cancers like uveal melanoma, positioning it against both large pharma oncology divisions and specialized biotech ADC developers.

Industry Context

IDEAYA Biosciences, Inc. operates in Precision Medicine Oncology / Biotech.

Key facts

Headquarters: South San Francisco, United States

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on IDEAYA Biosciences, Inc..

  • OptimUM-02 trial topline PFS data for darovasertib/crizotinib combination in metastatic uveal melanoma expected in Q1 2026, a key near-term catalyst.
  • IDE034 is the company's second proprietary TOP1 ADC, designed to be internalized only when target antigens are co-expressed on same tumor cell, enhancing selectivity and tolerability relative to monovalent antibody formats.
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • Feb 2026First patient enrolled in Phase 1 trial of IDE034, potential first-in-class B7H3/PTK7 bispecific TOP1 ADC
  • Feb 2026New Chief Development Officer appointment and inducement stock option grants for three newly hired employees
  • +2 moreTrack every material event for IDEAYA Biosciences, Inc. as it happens. Explore monitoring →
Get alerted when IDEAYA Biosciences, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

ADC/Targeted Oncology TherapiesLeading ADC developer with multiple approved therapies→Synthetic Lethality PlatformsMetabolic synthetic lethality focused oncology company→Uveal Melanoma TherapiesCo-developing darovasertib for uveal melanoma globally→

Compare IDEAYA Biosciences, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

IDEAYA Biosciences, Inc. operates in Precision Medicine Oncology / Biotech. See how the rest of the sector scores on the Cyborg framework.

Browse Precision Medicine Oncology / Biotech research →
NEW · MCP server

Ask your AI assistant about IDEAYA Biosciences, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare IDEAYA Biosciences, Inc. and its top competitor on Cyborg Score”
“What did IDEAYA Biosciences, Inc. do this quarter?”
“Is IDEAYA Biosciences, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does IDEAYA Biosciences, Inc. do?+
IDEAYA is a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies for cancer, integrating expertise in small-molecule drug discovery, structural...
What is IDEAYA Biosciences, Inc.'s Cyborg Score?+
IDEAYA Biosciences, Inc. has a Cyborg Score of 7/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are IDEAYA Biosciences, Inc.'s main competitors?+
Named competitors include ADC/Targeted Oncology Therapies, Synthetic Lethality Platforms, Uveal Melanoma Therapies. The full competitive landscape is in the AskCyborg report.
How can I get the full IDEAYA Biosciences, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the IDEAYA Biosciences, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track IDEAYA Biosciences, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.